药物涂层球囊对冠状动脉小血管原发病变的疗效被引量：4

在线阅读下载PDF

导出

摘要目的:探讨药物涂层球囊(DCB)对冠状动脉小血管原发病变的疗效和对心血管主要不良事件(MACE)的影响。方法:回顾性纳入因不稳定性心绞痛行DCB治疗并行冠状动脉造影复查的患者21例(DCB组),按照相似的临床特征匹配行药物洗脱支架(DES)治疗的患者21例(DES组)。比较两组术后8个月时靶病变晚期管腔丢失(LLL)、MACE和出血事件的发生率。结果:术后随访8个月,DCB组靶病变LLL显著小于DES组[(0.12±0.33)mm对(0.35±0.43)mm,P<0.01]。两组MACE事件发生率、出血事件发生率无统计学差异。结论:DCB应用于冠状动脉小血管原发病变介入治疗可以有效减少靶病变LLL,与DES相比,MACE、出血事件发生率无明显增加。

作者薛宪骏钱钧刘文武马永强孙公平

机构地区马鞍山市中心医院心内科苏州科技城医院心内科

出处《国际心血管病杂志》 2018年第4期245-247,共3页 International Journal of Cardiovascular Disease

基金马鞍山市科技计划项目(YL-2017-07)

关键词药物涂层球囊小血管原发病变经皮冠状动脉介入术

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献3

1陈韵岱,王建安,刘斌,季福绥,邱春光,乔树宾.药物涂层球囊临床应用中国专家共识[J].中国介入心脏病学杂志,2016,24(2):61-67. 被引量：205
2葛均波.开拓新兴介入技术发展多元介入治疗[J].中国介入心脏病学杂志,2013,21(1):1-1. 被引量：17
3柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量：2165

二级参考文献71

1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量：194
2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
3Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
4Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
5CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
6Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
7Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
8Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
9Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.
10Platlat Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS) study investigator. Inhibition of the platelet giycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med,1998, 338(21) :1488-1497.